Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
Cosmo Pharmaceuticals N.V. reports news across its life sciences business, including MedTech AI, dermatology, gastrointestinal disease programs, and contract development and manufacturing. Company updates frequently cover the GI Genius™ platform and real-time medical AI for endoscopy, dermatology assets such as Clascoterone 5% topical solution and Winlevi®, and gastroenterology research programs in bile acid diarrhea and distal ulcerative colitis.
Recurring disclosures also include annual results, recurring revenue trends, dividend actions, AGM voting outcomes, ESG reporting, board and remuneration matters, and capital-structure authorizations. Partnership and R&D collaboration announcements describe how Cosmo extends AI-enabled medical technology into additional clinical applications while maintaining a broader portfolio of pharmaceutical and CDMO activities.
Cosmo (OTC: CMOPF) reported H1 2026 results showing recurring revenues of €49.6 million, up 18% year-over-year, driven by Winlevi (+38%), Lialda (+35%) and CDMO (+14%). Total revenue was €50.2 million, slightly below H1 2025 due to lower project-based revenues.
The company completed Phase III for Clascoterone 5% topical solution in androgenetic alopecia with positive 12‑month data supporting chronic use and is preparing regulatory submissions in the US (Q1 2027) and Europe (Q2 2027). Cosmo also completed enrolment and dosing in its Phase II rifamycin SV enema trial for distal ulcerative colitis, with topline data expected Q4 2026, and continued the Phase II colesevelam MMX study.
Cosmo ended the period debt-free, with €205.1 million in cash, equivalents and investments, an equity ratio of 81.5%, and reaffirmed its 2026 guidance for total revenues of €105–110 million and EBITDA of €10.5–13.5 million.
Cosmo (OTC:CMOPF) will publish its Half-Year 2026 results on 23 July 2026 at 7:00 am CEST, followed by a live results webcast at 3:00 pm CEST.
The CEO and CFO will present financial and operational performance, strategy, and outlook, with Q&A and a three-month replay.
Cosmo (OTC:CMOPF) announced that its acne cream Winlevi (clascoterone 1% cream) was launched in Austria and Germany on June 1 by commercial partner InfectoPharm. Cosmo is the exclusive manufacturer, following European Commission approval in October 2025.
Cosmo describes Winlevi as a first-in-class topical androgen-receptor inhibitor, aimed at reducing sebum production and inflammation. Winlevi is already approved in numerous countries worldwide, with an Italy launch planned in September and additional registrations underway.
Cosmo (OTC:CMOPF) announced that partner Glenmark Specialty has launched Winlevi (clascoterone 10 mg/g cream) in key European markets, including the Nordics, Central and Eastern Europe, Spain, and via a partner in Portugal.
Winlevi, developed by Cosmo subsidiary Cassiopea, has EU marketing authorization for acne vulgaris in adults and adolescents, with Cosmo as exclusive manufacturer.
Cosmo (CMOPF) completed enrolment in its Phase II trial of rifamycin enema for distal ulcerative colitis and ulcerative proctitis. 77 patients were enrolled across 24 European sites. The bio-adhesive, locally acting formulation targets inflamed distal colon and rectum. Topline results are expected in fall 2026.
Cosmo Pharmaceuticals (OTC: CMOPF) reported positive 12-month Phase III results for Clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia. The program enrolled 1,465 subjects across 51 centers. Continuous treatment produced a statistically significant 2.39x improvement in Target Area Hair Count versus patients switched to vehicle, safety was comparable to vehicle, and patient satisfaction improved +24.5%. NDA and MAA work is underway with a U.S. filing planned for early 2027.
Cosmo Pharmaceuticals (CMOPF) reported that shareholders approved all items at the Ordinary Annual General Meeting on April 10, 2026.
10,354,065 ordinary shares were represented, equal to 59.02% of outstanding ordinary shares. Shareholders approved a €2.10 per share dividend; ex-dividend date is 24 April 2026 and payment date is 11 May 2026.
Cosmo (OTC: CMOPF) will present at NVIDIA GTC 2026 in San Jose, March 16–19. On March 19 at 10:00 CET Cosmo delivers a session titled "Engineering Medical Grade Platforms for Real Time AI" featuring MedTech AI leaders Nhan Ngo Dinh and Pietro Salvagnini.
The talk highlights Cosmo's real‑time clinical AI systems such as GI Genius and its use of NVIDIA accelerated computing for intra‑procedure detection, decision support, and workflow optimization.
Cosmo (OTC:CMOPF) has convened its Ordinary Annual General Meeting for 10 April 2026 in Amsterdam. Key agenda items include the Board report for 2025, appropriation of full-year 2025 results, a proposed distribution of €2.10 per share, a corporate name change to Cosmo N.V., director reappointments, adoption of remuneration policy, and authorisations to issue new ordinary and preferred shares.
Complete convening notice, explanatory notes and proxy, plus the Annual Report 2025 and ESG Report 2025, are available on the company website.
Cosmo Pharmaceuticals (OTC: CMOPF) reported FY2025 total revenue €104.2M with recurring revenues €88.1M (+15% YoY, 85% of total), EBITDA €9.5M (above guidance), cash, equivalents and investments €128.3M and no financial debt. The Board proposes a €2.10 dividend. 2026 guidance: recurring revenues €98–102M, total revenues €105–110M, EBITDA €10.5–13.5M and year-end cash ~€200M.